The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

Prebiotic composition including grape ferment, a first component, and a second component is provided. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide, or inulin. The first component is different from the second component, and a weight ratio of the grape ferment, the first component and the second component falls within the range of 1-2:1-2:1-2. Based on this, the prebiotic composition prepared by grape ferment can be used to promote intestinal health of a subject in need thereof and enhance antioxidation in the subject.

Prebiotic composition including grape ferment, a first component, and a second component is provided. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide, or inulin. The first component is different from the second component, and a weight ratio of the grape ferment, the first component and the second component falls within the range of 1-2:1-2:1-2. Based on this, the prebiotic composition prepared by grape ferment can be used to promote intestinal health of a subject in need thereof and enhance antioxidation in the subject.

A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.

A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.

A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.

The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.